US 2026/0295042 A1 · SWITCH RECEPTORS

Abstract

The present disclosure relates to the fields of molecular biology, more specifically cytokine receptors. The present disclosure also relates to methods of medical treatment and prophylaxis, particularly cellular immunotherapy.

Claims36

Dependent claims

A chimeric receptor polypeptide comprising:

(i) an extracellular portion comprising an IL23-binding domain;
(ii) an intracellular portion comprising the intracellular domains of IL12Rb2 (Interleukin-12 receptor beta 2);
and
(iii) a transmembrane domain that joins the extracellular portion and the intracellular portion.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

19/412,397Filed 8 Dec 2025

Priority

EP 23177793.96 Jun 2023

Published

1 Oct 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification19 codes

A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/31
Characterised by the recombinant expression of specific molecules in the cells of the immune system: chimeric antigen receptors [CAR]
A61K 40/34
Characterised by the recombinant expression of specific molecules in the cells of the immune system: antigenic peptides
A61K 40/35
Characterised by the recombinant expression of specific molecules in the cells of the immune system: cytokines

Switch receptors

Life of this patent

Abstract

Claims36

Switch receptors

Life of this patent

Abstract

Claims36